Aug 19, 2026 · 6 min
Moderna surges as beauty beats and furniture weakness split markets
Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy Sinks
The episode contrasts a breakthrough-driven biotech rally with uneven consumer-company results, then widens the lens to technology and long-term urban planning.
- 1Moderna and Merck shares surged after promising late-stage results for a personalized mRNA melanoma vaccine, though challenges remain.
- 2Estée Lauder beat fourth-quarter expectations and raised guidance, while La-Z-Boy reported weaker sales and a disappointing outlook.
- 3A companion discussion examines AI-enabled urban systems and Dubai’s long-term strategy for managing rapid population growth.
Don't miss
Moderna’s record surge after promising late-stage results for a personalized melanoma vaccine provides the episode’s clearest market-moving moment.
The brief
The market roundup opens with Moderna and Merck shares surging after promising late-stage results for a personalized mRNA melanoma vaccine, while its potential and remaining challenges remain in view.
Alexis Christoforous explains Estée Lauder’s rebound after a smaller-than-expected loss, stronger guidance, and investor focus on its portfolio of beauty brands.
La-Z-Boy moves in the opposite direction after a quarterly loss, lower sales, and a weak forecast raise questions about margins amid store, advertising, and digital investments.
The episode closes by previewing a smarter-cities discussion: AI-enabled urban systems and Dubai’s long-term development strategy offer different answers to rapid population growth.
What was said on this episode
11 statements · 7 positive · 3 negative · 1 neutral
Moderna shares rose more than 90% in premarket trading.
“The stock is nearly doubling here in the pre-market. It's up more than 90%.”
Listen at 0:41
Merck shares rose about 9% in premarket trading.
“And Merck is up about 9%.”
Listen at 0:46
The Moderna-Merck vaccine prevented recurrence or spread in high-risk melanoma patients.
“it succeeded in preventing cancer from returning or spreading in high-risk melanoma patients.”
Listen at 0:55
Moderna and Merck must demonstrate efficacy in tumor types beyond melanoma.
“The companies will need to prove that the vaccine works in other tumor types too, not just melanoma.”
Listen at 1:24
Estée Lauder fourth-quarter net sales exceeded $3.6 billion after rising over 6%.
“Net sales climbed more than 6% to $3.6 billion in the fiscal fourth quarter.”
Listen at 2:09
Estée Lauder’s turnaround is gaining momentum.
“Their turnaround is picking up steam.”
Listen at 2:14
La-Z-Boy swung to a quarterly loss exceeding $2 million.
“It swung to a loss of more than $2 million last quarter.”
Listen at 2:54
La-Z-Boy sales declined 3% last quarter.
“Sales fell 3%.”
Listen at 2:57
La-Z-Boy’s current-quarter sales forecast was below estimates.
“The furniture maker also gave a sales forecast for the current quarter that was below estimates.”
Listen at 2:58
AI will compress processes and accelerate smart-city operations.
“Essentially, AI will allow in the smart city space to compress a lot of things. the speed will change.”
Listen at 4:13
Dubai is using smart-city technology as a growth engine.
“Dubai is one city embracing such technology as a growth engine”
Listen at 4:20
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Alexis Christoforous
The Closing Bell on the Stock Movers Report
MACBooks & mentions
Economy of Scale
It extends the episode’s smarter-cities preview into questions about AI, infrastructure, and long-term urban growth.
Listen to the full episode and explore every guest, topic, and moment on PodLume.